Compare ABRDN Physical Gold Shares ETF (SGOL) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ABRDN Physical Gold Shares ETF vs GeneDx Holdings Corp — how do they compare? ABRDN Physical Gold Shares ETF trades at $39.92 (market cap $7.03B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: ABRDN Physical Gold Shares ETF is far larger — about 3.5× GeneDx Holdings Corp's market cap, and GeneDx Holdings Corp is more actively traded (734,640 versus 2,350,550). Which is the better fit depends on your goals — on Pluang, investors hold ABRDN Physical Gold Shares ETF for 57 Days and GeneDx Holdings Corp for 19 Days on average.
| SGOL | WGS | |
|---|---|---|
Market Cap | $7.03B | $2.02B |
Volume | 2,350,550 | 734,640 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $51.41 | $167.51 |
52-Week Low | $37.54 | $34.51 |
Typical Hold Time | 57 Days | 19 Days |
Enterprise Value | — | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SGOL trades at $39.31, up 0.74% today, while technical indicators show a bearish bias with moving averages and ADX signaling sell conditions. The stock lacks key financial ratio data such as P/E and P/B, limiting fundamental clarity. Recent gold-related news highlights pressure from rising Treasury yields and a firm dollar, though softer inflation data has provided some support.
The outlook remains cautious due to macroeconomic headwinds and incomplete financial disclosures. Risks include interest rate sensitivity and gold price volatility. Investors should seek updated SEC filings for fundamental metrics before considering a position.
GeneDx (WGS) trades at $67.73, down 1.17% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $454M in 2026 but faces profitability challenges with a -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth story with expanding genomic testing volumes but carries significant execution risk given negative profitability metrics. Upside potential exists if management can translate revenue growth into sustainable profits, though current cash flow trends and high valuation multiples warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ABRDN Physical Gold Shares ETF
SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
